Combination treatment with thrombopoietin receptor agonists (TPO-RA), immunosuppressants, and intravenous immunoglobulin G (IVIG) appears to be efficacious in the management of patients with severe refractory immune thrombocytopenia (ITP), according to a study published in the British Journal of Haematology.

Researchers evaluated the combination of ciclosporin A and mycophenolate mofetil (CSA/MMF; to inhibit T-cell activation), romiplostim or eltrombopag (to stimulate platelet production), and IVIG (to inhibit autoantibody-mediated platelet destruction) as a way to target 3 different mechanisms of ITP pathology.

- Article by Lauren Dembeck, PhD for HematologyAdvisor.com.  Photo courtesy of HematologyAdvisor.com.

Read More